Stephen J. Crocker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stephen J. Crocker has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Alessia Pellerino
Division of Neuro-Oncology, Department of Neuroscience “Rita Levi Montalcini”, University and City of Health and Science Hospital, Torino, Italy
36 shared publications - Alfonso Calvo
Program in Solid Tumors, Center for Applied Medical Research (CIMA), Cancer Center Clinica Universidad de Navarra (CCUN), University of Navarra, Avenida de Pío XII, 55, 31008 Pamplona, Spain
36 shared publications - Ana de Pablos-Aragoneses
Spanish National Cancer Research Centre New York, NY United States
36 shared publications - Anas Chaachou-Charradi
Surgery and Morphological Sciences Department Universitat Autònoma de Barcelona Barcelona Spain
36 shared publications - Andrea Rojas
Brain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
36 shared publications - Antonia Stammberger
TU Dresden, Institute of Immunology, Faculty of Medicine Carl Gustav Carus, 01307 Dresden, Germany
36 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (12)
Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum
Aging is a primary risk factor for disease progression in multiple sclerosis (MS). Because of this, treatments that can reduce the consequences of molecular aging, like senescence, have been proposed as a strategy to address disease progression. However, the effects of senolytics, a class of drugs which selectively ablate senescent cells, on the central nervous system are largely unknown. Here, we examined the effects of senolytic treatment on myelination and oligodendrocyte function in vivo using C57BL6/J mice and in vitro using primary rat oligodendrocyte cultures. Initial data showed that naïve young (3 to 4 mo) and aged (22 mo) C57BL6/J mice treated with dasatinib and quercetin (D+Q) developed significant demyelination compared to vehicle-treated controls, though no cell death was observed in the brain. In vitro, oligodendrocyte progenitor cells treated with D+Q in differentiation media exhibited significantly reduced myelin basic protein protein and morphological complexity, also without inducing cell death. Bulk RNA sequencing and ingenuity pathway analysis of D+Q treated oligodendrocytes identified differentially expressed genes associated with endoplasmic reticulum stress. These data suggest that D+Q evokes the unfolded protein response in oligodendrocytes, causing oligodendrocyte dysfunction and myelination failure. Due to the resemblance between oligodendrocytes treated with D+Q and those found in MS lesions, D+Q treatment offers a potential method to model an aspect of oligodendrocyte dysfunction relevant to MS. Therefore, understanding the mechanism by which D+Q perturb oligodendrocyte function may provide insight into some of the pathological features contributing to disease progression in MS.
- 17 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (12)
Open AccessSenolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum
Aging is a primary risk factor for disease progression in multiple sclerosis (MS). Because of this, treatments that can reduce the consequences of molecular aging, like senescence, have been proposed as a strategy to address disease progression. However, the effects of senolytics, a class of drugs which selectively ablate senescent cells, on the central nervous system are largely unknown. Here, we examined the effects of senolytic treatment on myelination and oligodendrocyte function in vivo using C57BL6/J mice and in vitro using primary rat oligodendrocyte cultures. Initial data showed that naïve young (3 to 4 mo) and aged (22 mo) C57BL6/J mice treated with dasatinib and quercetin (D+Q) developed significant demyelination compared to vehicle-treated controls, though no cell death was observed in the brain. In vitro, oligodendrocyte progenitor cells treated with D+Q in differentiation media exhibited significantly reduced myelin basic protein protein and morphological complexity, also without inducing cell death. Bulk RNA sequencing and ingenuity pathway analysis of D+Q treated oligodendrocytes identified differentially expressed genes associated with endoplasmic reticulum stress. These data suggest that D+Q evokes the unfolded protein response in oligodendrocytes, causing oligodendrocyte dysfunction and myelination failure. Due to the resemblance between oligodendrocytes treated with D+Q and those found in MS lesions, D+Q treatment offers a potential method to model an aspect of oligodendrocyte dysfunction relevant to MS. Therefore, understanding the mechanism by which D+Q perturb oligodendrocyte function may provide insight into some of the pathological features contributing to disease progression in MS.
- 21 December 2025
- Published by Elsevier in Neuroscience Letters
- Vol. 873, 138494
Recovery from cuprizone induced incontinence is not dependent upon remyelination
- 21 December 2025
- Published by Elsevier in Neuroscience Letters
- Vol. 873, 138494
Recovery from cuprizone induced incontinence is not dependent upon remyelination
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Table S16 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
Predictive analysis of patient-derived organotypic cultures (PDOC) treated with anti-TIMP1. Clinical information of samples treated in patient-derived organotypic brain cultures (PDOCs) of human brain metastasis with Anti-TIMP1 stratified accorded to their Immune Cluster. The table contains information corresponding to Supplementary Figure 5M-N.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S16 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
Predictive analysis of patient-derived organotypic cultures (PDOC) treated with anti-TIMP1. Clinical information of samples treated in patient-derived organotypic brain cultures (PDOCs) of human brain metastasis with Anti-TIMP1 stratified accorded to their Immune Cluster. The table contains information corresponding to Supplementary Figure 5M-N.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Table S10 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
GSEA_comparision between STAT3+ clusters of brain metastasis-associated astrocytes in human brain metastasis samples. Gene set enrichment analysis (GSEA) of upregulated and downregulated signatures comparing each STAT3+ cluster and the other clusters of brain metastasis-associated astrocytes. The table contains information corresponding to Figure 1F-I.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
GSEA_comparision between STAT3+ clusters of brain metastasis-associated astrocytes in human brain metastasis samples. Gene set enrichment analysis (GSEA) of upregulated and downregulated signatures comparing each STAT3+ cluster and the other clusters of brain metastasis-associated astrocytes. The table contains information corresponding to Figure 1F-I.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Table S17 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
GSEA analysis of proteomic data obtained from CD8+ T cells incubated with astrospheres conditioned medium. NES and statistics of the comparisons between the following experimental conditions: CD8+ lymphocytes were cultured with pSTAT3- astrospheres conditioned medium (CM) (D1) and wt (D2) or cKOGFAP-Timp1 (D2KO) pSTAT3+ astrospheres CM processed for phosphoproteomic analysis. The table contains information corresponding to Supplementary Figure 7B.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S17 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
GSEA analysis of proteomic data obtained from CD8+ T cells incubated with astrospheres conditioned medium. NES and statistics of the comparisons between the following experimental conditions: CD8+ lymphocytes were cultured with pSTAT3- astrospheres conditioned medium (CM) (D1) and wt (D2) or cKOGFAP-Timp1 (D2KO) pSTAT3+ astrospheres CM processed for phosphoproteomic analysis. The table contains information corresponding to Supplementary Figure 7B.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Table S9 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
GSEA_comparision between cluster 4 and cluster 5 of brain metastasis-associated astrocytes in human brain metastasis samples. Gene set enrichment analysis (GSEA) of upregulated and downregulated signatures comparing cluster number 4 and number 5 of human brain metastasis associated-astrocytes. The table contains information corresponding to Figure 1I.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
GSEA_comparision between cluster 4 and cluster 5 of brain metastasis-associated astrocytes in human brain metastasis samples. Gene set enrichment analysis (GSEA) of upregulated and downregulated signatures comparing cluster number 4 and number 5 of human brain metastasis associated-astrocytes. The table contains information corresponding to Figure 1I.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Table S14 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
Human brain metastases refractory to immune checkpoint blockade. Clinical information of samples from brain metastasis patients that responded to immune checkpoint blockade systemically but not in the brain. The table contains information corresponding to Figure 3H.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S14 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
Human brain metastases refractory to immune checkpoint blockade. Clinical information of samples from brain metastasis patients that responded to immune checkpoint blockade systemically but not in the brain. The table contains information corresponding to Figure 3H.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
A combined immunotherapy targeting local immunosuppression provides superior control of brain metastasis. Supplementary Figure 8 shows additional data corresponding to Figure 7.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
A combined immunotherapy targeting local immunosuppression provides superior control of brain metastasis. Supplementary Figure 8 shows additional data corresponding to Figure 7.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Table S24 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
Antibodies used for multiplex immunohistochemistry. Detailed information of antibodies used for multiplex.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S24 from TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells
Antibodies used for multiplex immunohistochemistry. Detailed information of antibodies used for multiplex.